Caplin Point Laboratories Ltd. is a very good buy for long-term investment perspective.As on 8th March 2018, it’s traded at approx. Rs.600 and 83% of Moneycontrol users recommend buying Caplin Labs. at the current price. It’s 5 Years and 3 years Return on Equity is 50.89% and 51.81% respectively as per Screener.
In layman’s terms if one had invested Rs.10000 before 5 years then it has grown to Rs. 80000 i.e. 8 times of the investment.
Pros and Cons as per Screener are as follow:
– Company has reduced debt.
– Company is virtually debt free.
– Company is expected to give good quarter
– Company has good consistent profit growth of 64.49% over 5 years
– Company has a good return on equity (ROE) track record: 3 Years ROE 51.81%
– The stock is trading at 13.78 times its book value
Caplin Point was established in 1990 to manufacture a range of ointments, creams, and other external applications.
The Company was listed in 1994 following its IPO which was oversubscribed 117 times, the proceeds of which were deployed in setting up a manufacturing facility at Pondicherry. Thereafter, the Company expanded its product range and increased its production capacity.
The Company focused on the emerging markets of Latin America, Caribbean, Francophone and Southern Africa and is today one of the leading suppliers of Pharmaceuticals in these regions, with over 2000 product licenses across the globe.
The Company is entering into the Regulated Markets for Injectables through its state of the art manufacturing plant, capable of handling Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages. The facility is approved by US FDA, EU-GMP, ANVISA-Brazil and INVIMA-Colombia.
All stock recommendations and comments are the opinion of writer.
Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion.
All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.
You should be aware of the risks involved in stock investing, and you use the material contained herein at your own risk. Neither this blog nor any of its suppliers guarantee its accuracy or validity, nor are they responsible for any errors or omissions which may have occurred. The analysis, ratings, and/or recommendations made by the blog, and/or any of its suppliers do not provide, imply, or otherwise constitute a guarantee of performance.
Accuracy and completeness cannot be guaranteed. Users should be aware of the risks involved in stock investments. It should not be assumed that future results will be profitable or will equal past performance, real, indicated or implied.
The material on this website are provided for information purpose only. Author/Blog/Website does not accept liability for your use of the website. The website is provided on an “as is” and “as available” basis, without any representations, warranties or conditions of any kind.
I am a full-stack engineer whose passion lies in building great products while enabling others to perform their roles more effectively. I have architect and built horizontally scalable back-ends; distributed RESTful API services; and web-based front-ends with modern, highly interactive Ajax UIs.
I deal with:
Mobile First, Responsive design
Using technologies :
+ASP.NET,C#,VB.NET,C++,MS SQL,ADO.NET,WCF ,MVC,Web API
+Ajax, JSON, HTML5, CSS3
+Mac OS X, Linux, Windows
My Qualities ,I believe :
Self-directed and passionate
Meticulous yet pragmatic
Leadership skills, integrity